The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Delaying Hepatitis C Treatment Could Be Detrimental

Back to News Homepage

Next

Hepatitis C Management: The Most Important Meal of the Day

Interferon Not Included: Say Goodbye to Hepatitis C

May 6, 2015

Print this page

Learn more about Bristol-Myers Squibb’s drugs that had a 93% cure rate in recent trials for Hepatitis C genotype 1.
Interferon Not Included

Newest Hepatitis C Drug Without Interferon Achieves 93 Percent Cure Rate

Written by David Heitz

Another pharmaceutical company appears headed to market with a drug that cures hepatitis C genotype 1, without interferon and ribavirin, in just 12 weeks.

Research published today in The Journal of the American Medical Association (JAMA) showed a combination of Bristol-Myers Squibb drugs daclatasvir, asunaprevir, and beclabuvir cured hepatitis C in 93 percent of 112 study participants with cirrhosis who had not previously been treated.

Continue reading this entire article:
http://www.healthline.com/health-news/newest-hepatitis-c-drug-without-interferon-achieves-93-percent-cure-rate-050515

No Comments - be the first!
Share
Share

Previous

Delaying Hepatitis C Treatment Could Be Detrimental

Back to News Homepage

Next

Hepatitis C Management: The Most Important Meal of the Day

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.